Identification ofN-Propylnoraporphin-11-yl 5-(1,2-Dithiolan-3-yl)pentanoate as a New Anti-Parkinson's Agent Possessing a Dopamine D2and Serotonin 5-HT1ADual-Agonist Profile

Haobo Zhang; Na Ye; Shanglin Zhou; Lin Guo; Longtai Zheng; Zhili Liu; Bo Gao; Xuechu Zhen; Ao Zhang

doi:10.1021/jm200347t

journal article Jun 02, 2011

Identification ofN-Propylnoraporphin-11-yl 5-(1,2-Dithiolan-3-yl)pentanoate as a New Anti-Parkinson's Agent Possessing a Dopamine D2and Serotonin 5-HT1ADual-Agonist Profile

Haobo Zhang

Na Ye

Shanglin Zhou Lin Guo

Longtai Zheng Zhili Liu

Bo Gao

Xuechu Zhen Ao Zhang

Journal of Medicinal Chemistry Vol. 54 No. 13 pp. 4324-4338 · American Chemical Society (ACS)

View at Publisher Save 10.1021/jm200347t

Topics

No keywords indexed for this article. Browse by subject →

References

72

[1]

Lilienfeld D. E. Neuroepidemiology (1993) 10.1159/000110320

[2]

Schapira A. H. Trends Pharmacol. Sci. (2009) 10.1016/j.tips.2008.10.005

[3]

Schapira A. H. Neurol. Clin. (2009) 10.1016/j.ncl.2009.04.004

[4]

Schapira A. H. Nat. Rev. Drug Discovery (2006) 10.1038/nrd2087

[5]

Schapira A. H. Mov. Disord. (2007) 10.1002/mds.21679

[6]

Nagatsu T. Parkinsonism and Related Disorders (2009) 10.1016/s1353-8020(09)70004-5

[7]

Calabresi P. Mov. Disord. (2008) 10.1002/mds.22019

[8]

Abbott A. Nature (2010) 10.1038/466s6a

[9]

Lieberman J. A. CNS Drugs (2004) 10.2165/00023210-200418040-00005

[10]

Yamamoto M. Expert Rev. Neurother. (2008) 10.1586/14737175.8.4.671

[11]

Rezak M. DM, Dis.-Mon. (2007) 10.1016/j.disamonth.2007.05.002

[12]

Stocchi F. Parkinsonism and Related Disorders (2009) 10.1016/s1353-8020(09)70836-3

[13]

Nutt J. G. Trends Neurosci. (2000) 10.1016/s1471-1931(00)00029-x

[14]

Olanow C. W. Trends Neurosci. (2000) 10.1016/s1471-1931(00)00030-6

[15]

Abdel-Salam O. M. CNS Neurol. Disord.: Drug Targets (2008) 10.2174/187152708786441867

[16]

Gottwald M. D. Drugs Today (2008) 10.1358/dot.2008.44.7.1217105

[17]

Ohno Y. Cent. Nerv. Syst. Agents Med. Chem. (2010) 10.2174/187152410791196341

[18]

Politis M. Sci. Transl. Med. (2010) 10.1126/scitranslmed.3000976

[19]

Santiago M. J. Neurosci. Res. (1998) 10.1002/(sici)1097-4547(19980601)52:5<591::aid-jnr11>3.0.co;2-5

[20]

Antonelli T. Synapse (2005) 10.1002/syn.20195

[21]

Dupre K. B. Neuropharmacology (2008) 10.1016/j.neuropharm.2008.08.031

[22]

Bishop C. J. Neurosci. Res. (2009) 10.1002/jnr.21978

[23]

McIntyre J. A. Drugs Future (2006) 10.1358/dof.2006.031.04.982108

[24]

Sorbera L. A. Drugs Future (2005) 10.1358/dof.2005.030.10.944018

[25]

Wadenberg M. L. G. Future Neurol. (2007) 10.2217/14796708.2.2.153

[26]

Bronzova J. Mov. Disord. (2010) 10.1002/mds.22948

[27]

Goetz C. G. Mov. Disord. (2007) 10.1002/mds.21226

[28]

Bibbiani F. Neurology (2001) 10.1212/wnl.57.10.1829

[29]

Tillner J. Mov. Disord. (2006)

[30]

Kuzhikandathil E. V. Neuropharmacology (2006) 10.1016/j.neuropharm.2006.05.030

[31]

Glennon J. C. Synapse (2006) 10.1002/syn.20330

[32]

Neumeyer J. L. (1985) 10.1007/978-3-642-70128-3_10

[33]

Zhang A. Chem. Rev. (2007) 10.1021/cr050263h

[34]

Zhang A. J. Med. Chem. (2007) 10.1021/jm060959i

[35]

Liu Z. J. Med. Chem. (2010) 10.1021/jm9015763

[36]

Cannon J. G. J. Med. Chem. (1988) 10.1021/jm00397a007

[37]

Cannon J. G. Chirality (1991) 10.1002/chir.530030105

[38]

Hedberg M. H. J. Chem. Soc., Chem. Commun. (1992) 10.1039/c39920000845

[39]

Hedberg M. H. J. Med. Chem. (1995) 10.1021/jm00004a011

[40]

Hedberg M. H. J. Med. Chem. (1996) 10.1021/jm960188q

[41]

Liu Z. Bioorg. Med. Chem. (2008) 10.1016/j.bmc.2008.08.056

[42]

Liu Z. Bioorg. Med. Chem. (2008) 10.1016/j.bmc.2008.05.077

[43]

Neumeyer J. L. J. Med. Chem. (1974) 10.1021/jm00256a014

[44]

Nechab M. Angew. Chem., Int. Ed. (2007) 10.1002/anie.200603780

[45]

Minkkila A. Eur. J. Med. Chem. (2009) 10.1016/j.ejmech.2009.01.007

[46]

Zhang, J.; Chen, X.; Zhen, X.; Zhang, A.Abstracts of Papers, 237th ACS National Meeting, Salt Lake City, UT, March 22–26, 2009, MEDI-311.

[47]

Neumeyer, J. L.; Baldessarini, R. L.R-(−)-11-Hydroxyaporphine and derivatives thereof. U.S. Patent US2010081651, 2010.

[48]

Li F. Bioorg. Med. Chem. (2010) 10.1016/j.bmc.2010.04.038

[49]

Zhang A. Org. Lett. (2003) 10.1021/ol027256p

[50]

Gillespie R. J. J. Med. Chem. (2009) 10.1021/jm800961g

Showing 50 of 72 references

Cited By

39

A Novel G Protein-Biased and Subtype-Selective Agonist for a G Protein-Coupled Receptor Discovered from Screening Herbal Extracts

Bingjie Zhang, Simeng Zhao · 2020

ACS Central Science

Metrics

39

Citations

72

References

Details

Published: Jun 02, 2011
Vol/Issue: 54(13)
Pages: 4324-4338

Authors

H

Haobo Zhang

Department of Pharmacology, Soochow University College of Pharmaceutical Sciences, Suzhou, China 215325

Department of Pharmacology, Soochow University College of Pharmaceutical Sciences, Suzhou, China 215325

Z

Zhili Liu

Yihang Intellitech Company Ltd., Beijing, China

B

Bo Gao

Department of Pharmacology, Soochow University College of Pharmaceutical Sciences, Suzhou, China 215325

X

Xuechu Zhen

Department of Pharmacology, Soochow University College of Pharmaceutical Sciences, Suzhou, China 215325

A

Ao Zhang

CAS Key Laboratory of Receptor Research; Synthetic Organic & Medicinal Chemistry Laboratory (SOMCL); Shanghai Institute of Materia Medica; Chinese Academy of Sciences; Shanghai

Cite This Article

Haobo Zhang, Na Ye, Shanglin Zhou, et al. (2011). Identification ofN-Propylnoraporphin-11-yl 5-(1,2-Dithiolan-3-yl)pentanoate as a New Anti-Parkinson's Agent Possessing a Dopamine D2and Serotonin 5-HT1ADual-Agonist Profile. Journal of Medicinal Chemistry, 54(13), 4324-4338. https://doi.org/10.1021/jm200347t

Identification ofN-Propylnoraporphin-11-yl 5-(1,2-Dithiolan-3-yl)pentanoate as a New Anti-Parkinson's Agent Possessing a Dopamine D2and Serotonin 5-HT1ADual-Agonist Profile

You May Also Like